Prostate cancer (PCa) is the first most diagnosed cancer in men in 112 countries and is the leading cause of cancer-related death among men in 48 countries [1] . The major risk factors of this disease include family history, ethnic groups and obesity in which family inheritance is considered as one of the most predisposing factors [2] .

Prostate cancer is diagnosed routinely based on elevated values of prostate-specific antigen (PSA), or analysis of prostate biopsy materials, and detection of DNA specific markers. The rectal examination and magnetic resonance imaging also could be used [3] [4] .

Treatment strategies of PC are varied and are dependent on the stage of the disease [5] including, androgen deprivation therapy (ADT) [6] , radiotherapy [7] , surgery [8] , chemotherapy [9] , and others [10] .

Despite the major improvements in diagnosis and treatment approaches, prostate cancer still remains a leading cause of cancer-related mortality among men globally [11] . Among 10 million clinically diagnosed PCa men, approximately 0.7 million are living with metastatic PCa, and more than 0.4 million deaths occur annually. This mortality rate is expected to increase by the coming years [12] .

Due to these facts and the resistant of the prostate cancer cells to various treatments, which can affect the course of the disease and survival [13] , there is an increasing need for other approaches of treatments with the emphases on the chemotherapy together with complete prostate prostatectomy [14] . Accordingly, this necessitates the search for new chemotherapy agents with higher efficacy and minimum side effects.

We believe that aminophosphonates compounds might be a candidate to this purpose due to their broad utilities such as anticancer [15] , enzyme inhibitors [16] , antibiotics [17] , fungicides [18] , anti-viral agents [19] , herbicides [20] and others [21] .

This work is an extension of our long ongoing research on organophosphonates compounds [22] - [24] , and is devoted to aminated cyclopropylmethylphosphonates, which demonstrated anti-pancreatic cancer activity [25] .

So, in pursue to our recently reported encouraging anti-pancreatic results of the novel cyclopropylmethylphosphonate compounds 3, we determined to investigate their potential against other types of tumours [25] .

Accordingly, the emphasis was on the prostate cancer due to the fact that it is considered to be one of the most aggressive and lethal cancers for men as mentioned above. The compounds in Scheme 1 were in vitro tested on human prostate cancer cell line PC-3 (The American Type Culture Collection, Manassas, VA, USA) and interestingly they showed impressive activity in suppression of the prostate cancer in the cell line as shown in Figure 1 .

From one side the results showed that, the incorporation of the amine group significantly boosted the activity against pancreatic cancer cells as depicted in Figure 1 . From the other side, while the aminated derivative diethyl ((1-(3-(isopropylamino)propyl)cyclopropyl)methyl)phosphonate 3a displayed mild potency in inhibiting pancreatic cell proliferation, compounds diethyl ((1-(3-(pentylamino)propyl)cyclopropyl)methyl)phosphonate 3b and diethyl (1-(4-(benzylamino)butyl)cyclopropyl)methyl)phosphonate 3c showed a high potential as anti-prostatic cancer by exhibiting a potent cell suppression at low micromolar concentrations with an IC50 of approximately 45 µM.

In summary, in addition to their anti-pancreatic efficacy, aminated cyclopropylmethylphosphonates compounds possessed notable anti-prostate cancer activity, precisely when an alkyl chain or benzylamine group was incorporated into the cyclopropylmethylphosphonate framework. These results will be an instigation for an in vivo futural experimental exploration.